Multimodal Study of the Human Brain Epilepsy Tissue (TIPI²)
The TIPI2 study is a blood and tissue collection protocol to create an annotated biorepository to support research in drug-resistant epilepsy.
The aim of the study will be to identify new pathophysiological pathways. For this purpose, the investigators will investigate with a multimodal approach blood and brain samples from patients undergoing a surgery for focal drug-resistant epilepsy. The adult patients will be enrolled either during the pre-surgical evaluation or right before the surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to investigate blood and brain samples from patients with drug-resistant epilepsy in order to identify new pathophysiological biomarkers.
The investigators will first conduct multimodal research, including:
- electrophysiological analyses
- immunohistochemistry and genetic studies
- biochemistry analyses
Samples will be stored at -80°C for future research.
Patients will undergo a follow-up evaluation within the 36 months following the surgery. New clinical data and biological samples will be collected then.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vincent M. Navarro, MD, PHD
- Phone Number: +33 01 42 16 19 40
- Email: Vincent.navarro@aphp.fr
Study Contact Backup
- Name: Aurélie Ms Hanin, PharmD, PhD
- Phone Number: +33 01 57 27 40 56
- Email: Aurelie.hanin@icm-institute.org
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Department of Neurology, Epilepsy Unit, Pitié-Salpêtrière Hospital
-
Contact:
- Vincent M. Navarro, MD, PHD
- Phone Number: +33 01 42 16 19 40
- Email: Vincent.navarro@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 yo or above
- patients with a focal drug-resistant epilepsy
- patients hospitalized for a pre-surgical evaluation or for an epilepsy surgery
- consent obtained from the patient, or legally authorized representative
- affiliated to a social security system
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: epileptic patients
All patients will be enrolled in the same arm.
Patients can be enrolled during the pre-surgical evaluation (group 1) or in the days preceding the surgery (group 2).
|
Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research. Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by immuno-histological methods
Time Frame: At the day of surgery; analyses are based on the post-operative tissues
|
The investigator will identify inflammatory cells (astrocytes, microglia, lymphocytes and neutrophil polynuclear cells) in the post-operative brain tissue, and will calculate if there is an increase of a part of these cells in the area, defined as the seizure onset zone, as compared to the non-epileptic areas.
|
At the day of surgery; analyses are based on the post-operative tissues
|
|
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by electrophysiological methods
Time Frame: At the day of surgery; analyses are based on the post-operative tissues
|
The investigator will record local field potentials and neuronal firing rate from post-operative tissues, and we will research an increase of the rate of interictal epileptiform discharges and of the frequency of the neuronal firing in the seizure-onset zone, as compared to those in non-epileptic areas.
|
At the day of surgery; analyses are based on the post-operative tissues
|
|
Identification of new pathophysiological mechanisms leading to focal drug-resistant epilepsy : analysis by RNA sequencing methods
Time Frame: At the day of surgery; analyses are based on the post-operative tissues
|
The investigator will measure the expression of mRNA in cells of different parts of the post-operative brain tissue, and we will research specific expression of mRNA in the Seizure onset zone, as compared to that in other non-epileptic areas.
|
At the day of surgery; analyses are based on the post-operative tissues
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of new pathophysiological mechanisms associated with the occurrence of a seizure : analysis of biomarkers by ELISA methods
Time Frame: from inclusion day to 36 months after the surgery
|
The investigator will measure several proteins by Elisa, and we will define if there is a specific increase of some proteins in the sample after a seizure, as compared to the level of these proteins far from a seizure.
|
from inclusion day to 36 months after the surgery
|
|
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of biomarkers by ELISA methods
Time Frame: from inclusion day to 36 months after the surgery
|
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
|
from inclusion day to 36 months after the surgery
|
|
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of blood cell subtypes by flow cytometry
Time Frame: from inclusion day to 36 months after the surgery
|
The investigator will measure the different blood cells by flow cytometry, and we will define if there is a specific increase of some cell populations in the sample from epileptic patients, as compared to the level of these cell populations in non-epileptic patients.
|
from inclusion day to 36 months after the surgery
|
|
Identification of new pathophysiological mechanisms associated with an active epilepsy : analysis of inflammation biomarkers by digital ultra-sensitive quantitation of proteins methods
Time Frame: from inclusion day to 36 months after the surgery
|
The investigator will measure several inflammatory proteins including cytokines, and we will define if there is a specific increase of some proteins in the sample from epileptic patients, as compared to the level of these proteins in non-epileptic patients.
|
from inclusion day to 36 months after the surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vincent M. Navarro, MD, PHD, APHP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Drug Resistant Epilepsy
- Epilepsy
- Investigative Techniques
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Health Care Facilities Workforce and Services
- Biological Specimen Banks
- Health Facilities
- Tissue Banks
- Blood Specimen Collection
Other Study ID Numbers
- APHP230479
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data are available upon reasonable request
The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.
Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.